Abstract 55P
Background
T cells engineered with chimeric antigen receptor (CAR-T) have shown success in treating hematological malignancies. However, the limited efficacy and potential side effects hinder the use of CAR-T in solid tumors. Research on this heterogeneous cell therapeutics at single-cell level can advance the current understanding and strategy of CAR-T therapy.
Methods
We used single-cell transcriptome analysis to characterize the transcriptional profile of stimulated CAR-T. T cells engineered with second-generation CAR constructs (with 4-1BB or CD28 co-stimulation domains) were stimulated with anti-CD3/CD28-coated beads and Nalm6 and subjected to microwell-based single-cell transcriptome analysis.
Results
A broad spectrum of transcripts was differentially expressed in T cells under various conditions. The sequence derived from the 3’-untranslated region of the CAR transcript distinguished CAR-T from non-transduced T cells within the analyzed cell population. CAR-T stimulation, mediated by either CD3/CD28 or CAR, significantly changed the gene-expression landscape compared to unstimulated CAR-Ts. Notably, CAR stimulation triggered higher expression of immune-related genes compared to CD3/CD28 stimulation. Additionally, comparing 4-1BB and CD28 co-stimulatory domains showed distinct transcriptional profiles contingent upon each co-stimulation signal.
Conclusions
This study revealed characteristic features of CAR-T signals affected by receptor structure (CD3/CD28 vs. CAR) and co-stimulation domain (4-1BB vs. CD28). These findings provide insights into a deeper understanding of CAR-T therapy, ultimately leading to the development of more effective CAR-T therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Research Foundation of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09